Table 1 Patient characteristics and relevant clinical data
From: Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma
Characteristics | P1 | P2 | P3 | P4 | P5 | P6 | P7 |
|---|---|---|---|---|---|---|---|
Age Decade | 70s | 60s | 50s | 50s | 40s | 60s | 60s |
Sex | Male | Male | Female | Female | Male | Male | Female |
Disease stage | II | IV | II | I | IV | IV | IV |
No. of prior therapies | 2 | 5 | 2 | 4 | 5 | 3 | 3 |
Prior lines of therapy | R-CHOP | R-CHOP | DA-EPOCH w/ IT MTX | Radiation | R-CHOP | R-CHOP | R-CHOP |
R-ICE | Benda-obinutuzumab | ICE | R-CHOP | R-ICE | R-ICE | R-ICE | |
R-ICE | R-ICE | BEAM + ASCT | BEAM + ASCT | BEAM + ASCT | |||
Hu5F9-G4 + rituxumab | BEAM + ASCT | FCR + AlloSCT | |||||
R-GEMOX | R-GEMOX | ||||||
Disease status | Relapsed | Relapsed, then refractory | Primary refractory | Relapsed | Relapsed | Relapsed | Relapsed |
Baseline (Ref. range) | |||||||
LDH, U/L (116-245 U/L) | 165 | 311 | 312 | 186 | 203 | 1276 | 297 |
CRP, mg/dL ( < 0.5 mg/dL) | 0 | ND | 3.5 | 0.6 | 0.3 | 4.1 | 1.4 |
Ferritin, ng/mL (20-300 ng/mL) | 110 | ND | 576 | 215 | 544 | 1228 | 229 |
ECOG PS | 1 | 1 | 2 | 0 | 1 | 1 | 0 |
Bridging therapy | No | No | Yes | No | Yes | Yes | No |
Maximum Grade CRS | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
Maximum Grade ICANS | 2 | 3 | 3 | 4 | 1 | 1 | 0 |
Tocilizumab or steroids | Both | Both | Both | Steroids | Tocilizumab | Tocilizumab | Tocilizumab |
Survival status | Deceased | Alive | Deceased | Alive | Alive | Alive | Alive |
Cause of Death | Second Malignancy | --- | Progressive lymphoma | --- | --- | --- | --- |
